Cancer Research UK
Cambridge Research Institute
Li Ka Shing Centre
Robinson Way
United Kingdom


Project partner until December 31, 2012

Institute presentation

The Cambridge Research Institute (CRI), based in the Li Ka Shing Centre, is a major new initiative in cancer research. The first researchers moved into the CRI in November 2006 and the centre was officially opened by Her Majesty the Queen on 2 February 2007. The Centre’s location on the Cambridge Biomedical Campus is designed to nurture collaborations between the CRI, the University of Cambridge, the surrounding biotechnology cluster and the 1100-bed Addenbrooke’s Hospital, which is the University teaching hospital and includes the Regional Cancer Centre. The Cambridge Biomedical Campus is also home to several University laboratories and research Institutes, including the MRC Laboratory of Molecular Biology, the Hutchison/MRC Research Centre, the Strangeways Research Laboratory and the Cambridge Institute for Medical Research.

There is a mixture of University and Cancer Research UK research groups at the CRI, however the Institute is run as a seamless scientific community with equal access to all core resources. Most PhD students at the CRI are registered with the University of Cambridge.

Research Strategy

The CRI undertakes research in four main areas:

  • Basic research into the cellular and molecular biology of cancer.
  • Research in molecular imaging, genomics, bioinformatics and biomolecular modelling.
  • Research focused on specific cancer sites, which will form a bridge between laboratory and clinic.
  • Clinical investigations including experimental medicine based clinical studies and, in the longer term, population based studies in screening and prevention. These will be conducted jointly with the University and National Health Service (NHS) clinical departments.

Although built on a strong platform of basic research, the overriding aim is that the CRI should be distinctive in its emphasis on the practical application of its science to clinical problems. As the CRI develops, this will require the assembly of large and well described sample sets, both for our own research but also to attract collaborations and hence resources from the pharmaceutical industry. The Anglian region provides an excellent opportunity to do this. In the future, the strategy for the CRI will include a significant component of activity outside the building, in order for us to achieve our clinical research goals.

In parallel, we are actively engaging with the wider scientific community of Cambridge through the Cambridge Cancer Centre, and to develop a clinical environment for research by the creation of a new Clinical Cancer Centre, in partnership with the Cambridge University Hospitals NHS Foundation Trust.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.